Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Director | October 01, 2026 | October 05, 2026 |
| MACROGENICS INCMGNX · Entity 6104 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.59 · Expires 2036-10-01 | Direct | 759 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 759 · Balance 759 F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
MACROGENICS INC
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,750 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Exercise / conversion · Acquired 3,750 · Balance 14,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,750 |
Reported balance
After 2026-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-19 · Grant · Acquired 3,750 · Balance 3,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2036-05-19 | Direct | 22,000 |
Reported balance
After 2026-05-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-19 · Grant · Acquired 22,000 · Balance 22,000 F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PROGENICS PHARMACEUTICALS INC
Report date June 19, 2020 · Filed June 23, 2020
Section 16 reporting ended · disclosed 2020-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2024-01-28 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-19 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2024-06-16 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.72 · Expires 2025-06-09 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.89 · Expires 2026-06-07 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.95 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-06-19 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-06-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.74 · Expires 2029-07-11 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-06-19 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:30 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 759 | $0.00 Strike: $31.59 | $0.00 |
DisclosureSEC source: 0001193125-26-414218 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 759 Underlying: Common Stock · 759 shares Expires 2036-10-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:30 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 627 | $0.00 Strike: $38.48 | $0.00 |
DisclosureSEC source: 0001193125-26-296249 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627 Underlying: Common Stock · 627 shares Expires 2036-07-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:30 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 17,901 | $0.00 Strike: $31.98 | $0.00 |
DisclosureSEC source: 0001193125-26-267663 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,901 Underlying: Common Stock · 17,901 shares Expires 2036-06-09 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001598502-26-000002 · wk-form4_1779308004.xml · derivative · entry 4 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-19 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001598502-26-000002 · wk-form4_1779308004.xml · derivative · entry 3 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001598502-26-000002 · wk-form4_1779308004.xml · derivative · entry 2 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. F2 · derivative.expiration_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:13 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001598502-26-000002 · wk-form4_1779308004.xml · nonDerivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 686 | $0.00 Strike: $35.24 | $0.00 |
DisclosureSEC source: 0001193125-26-142082 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 686 Underlying: Common Stock · 686 shares Expires 2036-04-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 643 | $0.00 Strike: $34.74 | $0.00 |
DisclosureSEC source: 0001193125-26-002367 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 643 Underlying: Common Stock · 643 shares Expires 2036-01-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:16 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,642 | $0.00 Strike: $14.13 | $0.00 |
DisclosureSEC source: 0001193125-25-230215 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,642 Underlying: Common Stock · 1,642 shares Expires 2035-10-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:15 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 3,314 | $0.00 Strike: $7.22 | $0.00 |
DisclosureSEC source: 0000950170-25-092976 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,314 Underlying: Common Stock · 3,314 shares Expires 2035-07-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:25 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 44,700 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0000950170-25-082374 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,700 Underlying: Common Stock · 44,700 shares Expires 2035-06-04 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:02 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001125345-25-000080 · wk-form4_1747944136.xml · derivative · entry 4 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-05-21 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:02 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000080 · wk-form4_1747944136.xml · derivative · entry 3 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:02 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 6,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000080 · wk-form4_1747944136.xml · derivative · entry 2 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. F2 · derivative.expiration_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:02 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 6,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-25-000080 · wk-form4_1747944136.xml · nonDerivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:05 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 3,788 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0000950170-25-050374 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,788 Underlying: Common Stock · 3,788 shares Expires 2035-04-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:21 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,785 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000950170-25-001210 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,785 Underlying: Common Stock · 2,785 shares Expires 2035-01-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:14 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,034 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0000950170-24-111468 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,034 Underlying: Common Stock · 2,034 shares Expires 2034-10-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:31 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,462 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0000950170-24-080555 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,462 Underlying: Common Stock · 2,462 shares Expires 2034-07-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| June 05, 2024 Filed Jun 13, 2024 23:14 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 44,700 | $0.00 Strike: $8.92 | $0.00 |
DisclosureSEC source: 0000950170-24-073234 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,700 Underlying: Common Stock · 44,700 shares Expires 2034-06-05 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:17 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001125345-24-000130 · wk-form4_1716499019.xml · derivative · entry 2 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-05-21 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:17 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 6,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000130 · wk-form4_1716499019.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F2 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:32 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000102 · wk-form4_1716409951.xml · derivative · entry 2 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. F2 · derivative.expiration_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:32 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000102 · wk-form4_1716409951.xml · nonDerivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 22:21 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 3,213 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0000950170-24-040496 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,213 Underlying: Common Stock · 3,213 shares Expires 2034-04-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:24 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 3,298 | $0.00 Strike: $6.24 | $0.00 |
DisclosureSEC source: 0000950170-24-001886 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,298 Underlying: Common Stock · 3,298 shares Expires 2034-01-02 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:51 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,345 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0000950170-23-051604 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,345 Underlying: Common Stock · 2,345 shares Expires 2033-10-02 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:53 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,884 | $0.00 Strike: $11.96 | $0.00 |
DisclosureSEC source: 0000950170-23-031704 · ownership.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,884 Underlying: Common Stock · 1,884 shares Expires 2033-07-03 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:47 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 36,700 | $0.00 Strike: $11.70 | $0.00 |
DisclosureSEC source: 0000899243-23-014900 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,700 Underlying: Common Stock · 36,700 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:59 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000100 · wk-form4_1685739551.xml · derivative · entry 2 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier. F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:59 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001125345-23-000100 · wk-form4_1685739551.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:16 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,053 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0000899243-23-010395 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,053 Underlying: Common Stock · 2,053 shares Expires 2033-04-03 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:30 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,862 | $7.19 Strike: $11.07 | $13,379.21 |
DisclosureSEC source: 0000899243-23-000615 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,862 Underlying: Common Stock · 1,862 shares Expires 2033-01-03 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:30 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,474 | $9.08 Strike: $14.33 | $13,378.02 |
DisclosureSEC source: 0000899243-22-032661 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,474 Underlying: Common Stock · 1,474 shares Expires 2032-10-03 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 17:52 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,279 | $5.87 Strike: $9.39 | $13,379.10 |
DisclosureSEC source: 0000899243-22-024930 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,279 Underlying: Common Stock · 2,279 shares Expires 2032-07-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:13 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 30,700 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0000899243-22-021648 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2032-06-07 F1 · derivative.exercise_date: This annual stock option award was made on the date of the 2022 Annual Meeting of Stockholders pursuant to the company's Non-Employee Director Compensation Program and shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders. Read SEC document |
| May 19, 2022 Filed May 24, 2022 01:06 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 20,640 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001125345-22-000063 · wf-form4_165335437160079.xml · derivative · entry 2 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,640 Underlying: Common Stock · 20,640 shares Expires 2032-05-19 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. F2 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 19, 2022 Filed May 24, 2022 01:06 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001125345-22-000063 · wf-form4_165335437160079.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:06 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,753 | $4.86 Strike: $7.92 | $13,379.58 |
DisclosureSEC source: 0000899243-22-013710 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,753 Underlying: Common Stock · 2,753 shares Expires 2032-04-01 F1 · price: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:25 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,329 | $5.15 Strike: $8.70 | $12,001.34 |
DisclosureSEC source: 0000899243-22-000693 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,329 Underlying: Common Stock · 2,329 shares Expires 2032-01-03 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 23:45 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,385 | $5.03 Strike: $8.54 | $12,000.60 |
DisclosureSEC source: 0000899243-21-039329 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,385 Underlying: Common Stock · 2,385 shares Expires 2031-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:05 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,513 | $4.78 Strike: $8.02 | $12,000.58 |
DisclosureSEC source: 0000899243-21-027625 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,513 Underlying: Common Stock · 2,513 shares Expires 2031-07-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:18 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001125345-21-000071 · wf-form4_162130066448767.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:09 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 2,121 | $5.66 Strike: $9.08 | $11,999.98 |
DisclosureSEC source: 0000899243-21-014969 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,121 Underlying: Common Stock · 2,121 shares Expires 2031-04-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 23:05 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0000899243-21-011698 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a three year period. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:47 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $7.62 | $0.00 |
DisclosureSEC source: 0000899243-21-000792 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 1,575 shares Expires 2031-01-04 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 21:30 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 8,878 | $1.35 Strike: $2.26 | $12,001.28 |
DisclosureSEC source: 0001209191-20-053277 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,878 Underlying: Common Stock · 8,878 shares Expires 2030-10-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:27 UTC | Cogent Biosciences, Inc. UMRX · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 38,487 | $0.31 Strike: $0.47 | $12,000.25 |
DisclosureSEC source: 0001209191-20-041016 · doc4.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,487 Underlying: Common Stock · 38,487 shares Expires 2030-07-01 F1 · shares: The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant. F2 · derivative.exercise_date: This option is fully vested at time of grant. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:47 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $5.74 | Not disclosed |
DisclosureSEC source: 0001437749-20-013673 · rdgdoc.xml · derivative · entry 7 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2029-07-11 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. F1 · derivative.exercise_date: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Each of these options is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.